JP5669224B2 - 医薬組成物 - Google Patents
医薬組成物 Download PDFInfo
- Publication number
- JP5669224B2 JP5669224B2 JP2012532076A JP2012532076A JP5669224B2 JP 5669224 B2 JP5669224 B2 JP 5669224B2 JP 2012532076 A JP2012532076 A JP 2012532076A JP 2012532076 A JP2012532076 A JP 2012532076A JP 5669224 B2 JP5669224 B2 JP 5669224B2
- Authority
- JP
- Japan
- Prior art keywords
- drop
- depression
- treatment
- growth factor
- nerve growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
双極性障害
不安障害
月経前症候群(PMS)
月経前不快気分障害(PMDD)
その他の心理的障害
うつ病、または他の精神病状の憎悪
睡眠障害
緊張性頭痛
慢性疲労症候群
便秘
当技術分野では、便秘のような病状の二次的影響を克服するために、気分の落ち込みや不安障害の治療に焦点を当てることが必要である。
禁断症状
神経成長因子
EXAMPLEI
実施例I
実施例II
実施例III
実施例IV
実施例V
実施例VI
実施例VII
実施例VIII
実施例IX
(一日1錠から一日4分の3錠への低下)
実施例X
実施例XI
実施例XII
実施例XIII
実施例XIV
実施例XV
実施例XVI
実施例XVII
実施例XVIII
実施例XIX
実施例XX
実施例XXI
実施例XXII
実施例XXIII
[項目1]
禁断症状を緩和することに有効な投与量で神経成長因子を、それを必要とする対象に投与することを含む禁断症状を緩和する方法。
[項目2]
前記禁断症状は糖類、炭水化物、アルコール、ニコチン、コカイン、アンフェタミン、アヘン剤および非アヘン鎮痛剤の禁断症状からなる群から選択される項目1に記載の方法。
[項目3]
前記神経成長因子は舌下、頬側、経口飲薬、皮下、皮内、または静脈注射からなる群から選択される様式によって投与される項目1に記載の方法。
[項目4]
前記神経成長因子は舌下で投与される項目3に記載の方法。
[項目5]
前記神経成長因子は一日に0.001〜1マイクログラムの毎日投与量で投与される項目1に記載の方法。
[項目6]
前記神経成長因子は一日に0.01〜0.1マイクログラムの毎日投与量で投与される項目1に記載の方法。
[項目7]
前記神経成長因子は神経成長因子のβサブユニットである項目1に記載の方法。
Claims (6)
- 禁断症状を治療することに有効な投与量の神経成長因子を含み、
前記禁断症状は、糖類、炭水化物およびアルコールの禁断症状からなる群から選択される、前記禁断症状を緩和する医薬組成物。 - 前記組成物は薬学的に許容可能な担体、賦形剤または希釈剤を更に含む請求項1に記載の医薬組成物。
- 各投与単位に0.001〜10マイクログラムを含む請求項1または2に記載の医薬組成物。
- 各投与単位に0.05〜1マイクログラムを含む請求項1から3の何れか1項に記載の医薬組成物。
- 各投与単位に0.01〜0.1マイクログラムを含む請求項1から4の何れか1項に記載の医薬組成物。
- 前記神経成長因子はNGFのβサブユニットである請求項1から5の何れか1項に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/573,706 | 2009-10-05 | ||
US12/573,706 US8367610B2 (en) | 2002-11-07 | 2009-10-05 | Method of treating cravings by administration of nerve growth factor |
PCT/US2010/043957 WO2011043858A1 (en) | 2009-10-05 | 2010-07-30 | Method of treating cravings by administration of nerve growth factor |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013506666A JP2013506666A (ja) | 2013-02-28 |
JP2013506666A5 JP2013506666A5 (ja) | 2013-05-02 |
JP5669224B2 true JP5669224B2 (ja) | 2015-02-12 |
Family
ID=43857053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012532076A Expired - Fee Related JP5669224B2 (ja) | 2009-10-05 | 2010-07-30 | 医薬組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8367610B2 (ja) |
EP (1) | EP2485748B1 (ja) |
JP (1) | JP5669224B2 (ja) |
AU (1) | AU2010303903B2 (ja) |
CA (1) | CA2776132A1 (ja) |
IL (1) | IL218479A0 (ja) |
WO (1) | WO2011043858A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8367610B2 (en) * | 2002-11-07 | 2013-02-05 | Beech Tree Labs, Inc. | Method of treating cravings by administration of nerve growth factor |
EP2800606A4 (en) * | 2012-01-05 | 2015-07-15 | Beech Tree Labs Inc | METHOD OF TREATING PAIN BY ADMINISTERING NERVE GROWTH FACTOR |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294520B1 (en) * | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
DE4016776A1 (de) * | 1990-04-05 | 1991-10-17 | Mtu Friedrichshafen Gmbh | Aufladegruppe mit steuerbaren ladeluftverdichtern fuer eine brennkraftmaschine |
IL109280A0 (en) * | 1993-04-15 | 1994-07-31 | Regeneron Pharma | Neurotrophins for treatment of depression |
US6024734A (en) * | 1994-03-31 | 2000-02-15 | Brewitt; Barbara A. | Treatment methods using homeopathic preparations of growth factors |
US20020049422A1 (en) * | 1994-03-31 | 2002-04-25 | Brewitt Barbara A. | Homeopathic preparations |
US6090781A (en) * | 1996-11-06 | 2000-07-18 | Genentech, Inc. | Stabilizing formulation for NGF |
US6663899B2 (en) * | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6284540B1 (en) * | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
US7273618B2 (en) * | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
CN1101224C (zh) * | 1999-10-20 | 2003-02-12 | 林德球 | 一种戒心瘾注射液 |
US20010052137A1 (en) * | 2000-03-01 | 2001-12-13 | Trustees Of The University Of Pennsylvania | Axin domain-like polypeptide inhibitors of glycogen synthase kinase 3 beta activity and activators of wnt signaling |
US7084126B1 (en) * | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
US20040127409A1 (en) * | 2002-11-07 | 2004-07-01 | Milkhaus Laboratory, Inc. | Method of treatment of psychological conditions by administration of nerve growth factor |
US8367610B2 (en) * | 2002-11-07 | 2013-02-05 | Beech Tree Labs, Inc. | Method of treating cravings by administration of nerve growth factor |
-
2009
- 2009-10-05 US US12/573,706 patent/US8367610B2/en not_active Expired - Fee Related
-
2010
- 2010-07-30 EP EP10822382.7A patent/EP2485748B1/en not_active Not-in-force
- 2010-07-30 WO PCT/US2010/043957 patent/WO2011043858A1/en active Application Filing
- 2010-07-30 CA CA2776132A patent/CA2776132A1/en not_active Abandoned
- 2010-07-30 JP JP2012532076A patent/JP5669224B2/ja not_active Expired - Fee Related
- 2010-07-30 AU AU2010303903A patent/AU2010303903B2/en not_active Ceased
-
2012
- 2012-03-05 IL IL218479A patent/IL218479A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2010303903A1 (en) | 2012-03-15 |
AU2010303903B2 (en) | 2014-04-17 |
EP2485748B1 (en) | 2014-07-02 |
EP2485748A4 (en) | 2013-03-20 |
US20100093631A1 (en) | 2010-04-15 |
EP2485748A1 (en) | 2012-08-15 |
US8367610B2 (en) | 2013-02-05 |
IL218479A0 (en) | 2012-04-30 |
CA2776132A1 (en) | 2011-04-17 |
WO2011043858A1 (en) | 2011-04-14 |
JP2013506666A (ja) | 2013-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vaughn McCall et al. | A polysomnography study of eszopiclone in elderly patients with insomnia | |
WO2006055854A2 (en) | Methods for reducing the side effects associated with mirtazapine treatment | |
US20070270347A1 (en) | Methods of Treating Constipation by Administration of Nerve Growth Factor | |
Gelenberg et al. | Psychoses | |
US20230372335A1 (en) | TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR | |
WO2020028810A1 (en) | Compositions and methods for treating brain-gut disorders | |
KR20230004670A (ko) | 다리도렉산트의 의학적 용도 | |
JP5669224B2 (ja) | 医薬組成物 | |
US20230145635A1 (en) | Treatment of menstrual cycle-induced symptoms | |
US20200038418A1 (en) | Methods of treating autism spectrum disorder using aminosterol compositions | |
US20210315907A1 (en) | Compositions and methods for treating brain-gut disorders | |
US20240115550A1 (en) | Treatment of mental disorders | |
McGoldrick | Alternative and complimentary methods in the treatment of sleep disorders and/or insomnia. | |
US20090318426A1 (en) | Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders | |
Morgenthaler et al. | Scientific Reports on GHB |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130311 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130311 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140708 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141118 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141211 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5669224 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |